A look at the results of the recently completed project, which aimed to develop an holistic monitoring system via process integration to more effectively control clinical trial risks beyond isolated RBM strategies.
A look at the results of the recently completed project, which aimed to develop an holistic monitoring system via process integration to more effectively control clinical trial risks beyond isolated RBM strategies.
Key considerations for successful implementation in decentralized clinical trials.
Finalizing protocols, aligning teams, and staying engaged headline best practices.
Almac provides an overview of their clinical technologies branch, their IRT offerings, and the current changes to the clinical development industry.
Capacity management and stability offer value for clients, their employees and FSP vendors.
Capacity management and stability offer value for clients, their employees and FSP vendors.
A review of a recent FSP in which the CRO partner assumed clinical monitoring and site support responsibility for more than 50 ongoing trials.
The integration of pre-screening all patients for eligibility in oncology studies.
This article discusses the adoption of RBQM in academic settings and the lessons that were learned.
The GS1 Standards will enable more efficient processes at institutions that are already using an electronic inventory system to manage investigational products.
Survey uncovers key best practices that sponsors, CROs, and sites should consider when faced with patient enrollment challenges.
The pandemic has thus far disproportionally impacted minority populations, and our ongoing failure to adequately represent all patients regardless of demographic background has never been more important to remedy than it is today, writes ACRP Workforce Innovation Officer Beth Harper.
George Clinical's Managing Director discusses the concern biopharma companies have with CFDA's slow drug and medical device approvals.
Medicines development and clinical research are among the most heavily regulated activities on a global basis.
With the ever changing regulatory landscape, outsourcing non-core activities is a flexible approach to managing resources and remaining compliant with NCO requirements for the entire generic portfolio.
During an audit, the FDA investigates six areas to determine whether a site is in compliance with federal drug accountability regulations-can sponsors answer them?
Mobile health devices are poised to transform medical care-and with it the medical device market.
The EU is launching a major transition within their legislation for medical and in vitro diagnostic devices. This transition is important and should include assessing the financial viability of the pipeline, expanding data collection, and locking in soon-to-be-scarce notified body resources.
CRO's and sponsors are taking clinical trials to homes. These in-home trials can address participation issues and provide added convenience plus support for patients, but they also come with their own set of risks.
Since the emergence of the independent IRB sector, sponsors have found that regulatory and ethical review by a single IRB yields important benefits with respect to efficiency, high quality, and consistency in human research protections.
Since the emergence of the independent IRB sector, sponsors have found that regulatory and ethical review by a single IRB yields important benefits with respect to efficiency, high quality, and consistency in human research protections.
A critical part of clinical trial conduct is providing medical guidance by the responsible medical monitor to investigative sites and various operations team members, including, but not limited to, clinical research associates and clinical study managers.
In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical, but how do you translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified?
This brief overview of Kazakhstan presented by Vlad Bogin will help you get acquainted with this emerging clinical trial location.
Here are four trends to watch as researchers continue to make headway in the development of biomarkers for cancer immunotherapy.
Supply chain strategies require a close look at the regulatory factors and the drug import hurdles and hopes in the region.
Supply chain strategies require a close look at the regulatory factors and the drug import hurdles and hopes in the region.